These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38886718)

  • 41. Cost-effectiveness analysis of patient self-testing therapy of oral anticoagulation.
    Kantito S; Saokaew S; Yamwong S; Vathesatogkit P; Katekao W; Sritara P; Chaiyakunapruk N
    J Thromb Thrombolysis; 2018 Feb; 45(2):281-290. PubMed ID: 29181693
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness of denosumab for high-risk postmenopausal women with osteoporosis in Thailand.
    Pongchaiyakul C; Nanagara R; Songpatanasilp T; Unnanuntana A
    J Med Econ; 2020 Jul; 23(7):776-785. PubMed ID: 32063082
    [No Abstract]   [Full Text] [Related]  

  • 44. Cost-Effectiveness Analysis of Ultrasound Surveillance for Cholangiocarcinoma in an Endemic Area of Thailand.
    Laopachee P; Siripongsakun S; Sangmala P; Chanree P; Hiranrat P; Srisittimongkon S
    Asian Pac J Cancer Prev; 2023 Dec; 24(12):4117-4125. PubMed ID: 38156846
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Analyzing cost-effectiveness of ulnar and median nerve transfers to regain forearm flexion.
    Wali AR; Park CC; Brown JM; Mandeville R
    Neurosurg Focus; 2017 Mar; 42(3):E11. PubMed ID: 28245686
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.
    Le V; Zhong L; Narsipur N; Hays E; Tran DK; Rosario K; Wilson L
    J Manag Care Spec Pharm; 2021 Mar; 27(3):327-338. PubMed ID: 33645243
    [No Abstract]   [Full Text] [Related]  

  • 47. Economic evaluation of policy options for prevention and control of cervical cancer in Thailand.
    Praditsitthikorn N; Teerawattananon Y; Tantivess S; Limwattananon S; Riewpaiboon A; Chichareon S; Ieumwananonthachai N; Tangcharoensathien V
    Pharmacoeconomics; 2011 Sep; 29(9):781-806. PubMed ID: 21838332
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness of warfarin care bundles and novel oral anticoagulants for stroke prevention in patients with atrial fibrillation in Thailand.
    Ng SS; Nathisuwan S; Phrommintikul A; Chaiyakunapruk N
    Thromb Res; 2020 Jan; 185():63-71. PubMed ID: 31770689
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The cost-effectiveness analysis of laparoscopic hepatectomy compared with open liver resection in the early stage of hepatocellular carcinoma: a decision-analysis model in Thailand.
    Singhirunnusorn J; Niyomsri S; Dilokthornsakul P
    HPB (Oxford); 2022 Feb; 24(2):183-191. PubMed ID: 34238678
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-Utility Analysis of Vasoconstrictors Plus Albumin in the Treatment of Thai Patients with Type 1 Hepatorenal Syndrome.
    Sangroongruangsri S; Kittrongsiri K; Charatcharoenwitthaya P; Sobhonslidsuk A; Chaikledkaew U
    Clinicoecon Outcomes Res; 2021; 13():703-715. PubMed ID: 34349534
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-Effectiveness of Cardiac Resynchronization Therapy in Patients with Heart Failure in Thailand.
    Permsuwan U; Phrommintikul A; Silavanich V
    Clinicoecon Outcomes Res; 2020; 12():579-588. PubMed ID: 33116697
    [TBL] [Abstract][Full Text] [Related]  

  • 52. COST-UTILITY ANALYSIS OF MULTIPLE SCLEROSIS TREATMENT IN THAILAND.
    Chanatittarat C; Chaikledkaew U; Prayoonwiwat N; Siritho S; Pasogpakdee P; Apiwattanakul M; Riewpaiboon A; Thavorncharoensap M
    Int J Technol Assess Health Care; 2018; 34(6):584-592. PubMed ID: 30560761
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Economic Evaluation of Human Rotavirus Vaccine in Thailand.
    Saokaew S; Prasitsuebsai W; Bibera GL; Kengkla K; Zhang XH; Oh KB; Lee C
    Infect Dis Ther; 2019 Sep; 8(3):397-415. PubMed ID: 31197662
    [TBL] [Abstract][Full Text] [Related]  

  • 54. International Cost-Effectiveness Analysis of Durvalumab in Stage III Non-Small Cell Lung Cancer.
    Kareff SA; Han S; Haaland B; Jani CJ; Kohli R; Aguiar PN; Huang Y; Soo RA; Rodríguez-Perez Á; García-Foncillas J; Dómine M; de Lima Lopes G
    JAMA Netw Open; 2024 May; 7(5):e2413938. PubMed ID: 38814640
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lateral lumbar interbody fusion (LLIF) reduces total lifetime cost compared with posterior lumbar interbody fusion (PLIF) for single-level lumbar spinal fusion surgery: a cost-utility analysis in Thailand.
    Boonsirikamchai W; Phisalpapra P; Kositamongkol C; Korwutthikulrangsri E; Ruangchainikom M; Sutipornpalangkul W
    J Orthop Surg Res; 2023 Feb; 18(1):115. PubMed ID: 36797750
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness of a hypothetical cell or gene therapy cure for sickle cell disease.
    Salcedo J; Bulovic J; Young CM
    Sci Rep; 2021 May; 11(1):10838. PubMed ID: 34035408
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model.
    Patel JJ; Mendes MA; Bounthavong M; Christopher ML; Boggie D; Morreale AP
    J Eval Clin Pract; 2012 Apr; 18(2):247-55. PubMed ID: 20846318
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-utility and budget impact analysis of drug treatments in pulmonary arterial hypertension associated with congenital heart diseases in Thailand.
    Thongsri W; Bussabawalai T; Leelahavarong P; Wanitkun S; Durongpisitkul K; Chaikledkaew U; Teerawattananon Y
    Expert Rev Pharmacoecon Outcomes Res; 2016 Aug; 16(4):525-36. PubMed ID: 26566873
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost-effectiveness analysis of pharmacist interventions in patients with heart failure in Thailand.
    Arunmanakul P; Chaiyakunapruk N; Phrommintikul A; Ruengorn C; Permsuwan U
    J Am Pharm Assoc (2003); 2022; 62(1):71-78. PubMed ID: 34756525
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mass media promotion of a smartphone smoking cessation app: modelled health and cost-saving impacts.
    Nghiem N; Leung W; Cleghorn C; Blakely T; Wilson N
    BMC Public Health; 2019 Mar; 19(1):283. PubMed ID: 30849943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.